We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Nobel Prize Awarded to Investigators of Telomeres and Telomerase

By LabMedica International staff writers
Posted on 12 Oct 2009
The 2009 Nobel Prize in Physiology or Medicine was awarded to three investigators who showed how chromosomes are completely copied during cell divisions and how they are protected against degradation. More...


Dr. Elizabeth Blackburn, professor of biology and physiology at the University of California, San Francisco (USA), and Dr. Jack Szostak, professor of genetics at Massachusetts General Hospital (Boston, USA) discovered that a unique DNA sequence in the telomeres protects the chromosomes from degradation. Dr. Carol Greider, professor of molecular biology and genetics at Johns Hopkins University (Baltimore, MD, USA) and Dr. Blackburn identified telomerase, the enzyme that makes telomere DNA.

These discoveries explained how the ends of the chromosomes are protected by the telomeres and that they are built by telomerase.

Telomeres are extensions of the linear, double-stranded DNA molecules of which chromosomes are composed, and are found at each end of both of the chromosomal strands. In most eukaryotes telomeres consist of several thousand repeats of the specific nucleotide sequence TTAGGG and occur in organisms ranging from slime molds to humans.

The telomeres become shorter each time a cell divides. When the telomeres reach a specific short length, they signal the cell to stop dividing. Therefore, cellular aging, as marked by telomere shortening, is not based on the passage of time but rather on rounds of DNA replication.

Cancer cells escape telomere loss by switching on the gene that encodes for the enzyme telomerase. This enzyme is a reverse transcriptase that has an RNA template and a catalytic portion. At each round of DNA replication, telomerase adds onto the existing telomeres the nucleotides that would otherwise have been lost, thus maintaining a constant telomere length. Thus, telomerase acts as an "immortalizing" enzyme. In addition, it has several associated proteins whose roles are still under investigation.

Using the TRAP assay (telomeric repeat amplification protocol), it has been found that about 90% of all human tumors produce telomerase, whereas the only normal adult somatic cells that produce telomerase are stem cell populations found, for example, in skin, the hematopoietic system, germ cells, and gut epithelia.

The presence or absence of telomerase is the most specific property that distinguishes cancer cells from normal cells. This difference is currently under investigation as a diagnostic tool. If a chemical could be found to interfere with telomerase activity in cancer cells, an effective control of this disease might be found. Several candidate substances have been identified and are undergoing extensive studies in animals.

Related Links:
University of California, San Francisco
Massachusetts General Hospital
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Automated Immunoassay Analyzer
SuperFlex™
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.